Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Review

Requirements for a minimum standard of care for phenylketonuria: the patients’ perspective

Authors: Tobias S Hagedorn, Paul van Berkel, Gregor Hammerschmidt, Markéta Lhotáková, Rosalia Pasqual Saludes

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Phenylketonuria (PKU, ORPHA716) is an inherited disorder that affects about one in every 10,000 children born in Europe. Early and continuous application of a modified diet is largely successful in preventing the devastating brain damage associated with untreated PKU. The management of PKU is inconsistent: there are few national guidelines, and these tend to be incomplete and implemented sporadically. In this article, the first-ever pan- European patient/carer perspective on optimal PKU care, the European Society for Phenylketonuria and Allied Disorders (E.S.PKU) proposes recommendations for a minimum standard of care for PKU, to underpin the development of new pan-European guideline for the management of PKU. New standards of best practice should guarantee equal access to screening, treatment and monitoring throughout Europe. Screening protocols and interpretation of screening results should be standardised. Experienced Centres of Expertise are required, in line with current European Union policy, to guarantee a defined standard of multidisciplinary treatment and care for all medical and social aspects of PKU. Women of childbearing age require especially intensive management, due to the risk of severe risks to the foetus conferred by uncontrolled PKU. All aspects of treatment should be reimbursed to ensure uniform access across Europe to guideline-driven, evidence-based care. The E.S.PKU urges PKU healthcare professionals caring for people with PKU to take the lead in developing evidence based guidelines on PKU, while continuing to play an active role in serving as the voice of patients and their families, whose lives are affected by the condition.
Appendix
Available only for authorised users
Literature
1.
go back to reference Loeber JG: Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007, 30: 430-438. 10.1007/s10545-007-0644-5.CrossRef Loeber JG: Neonatal screening in Europe; the situation in 2004. J Inherit Metab Dis. 2007, 30: 430-438. 10.1007/s10545-007-0644-5.CrossRef
2.
go back to reference Scriver CR, Kaufman S: Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, Vogelstein B. 2001, New York: McGraw-Hill, 1667-1724. 8 Scriver CR, Kaufman S: Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. The Metabolic and Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, Vogelstein B. 2001, New York: McGraw-Hill, 1667-1724. 8
3.
go back to reference Blau N, van Spronsen FJ, Levy HL: Phenylketonuria. Lancet. 2010, 376: 1417-1427. 10.1016/S0140-6736(10)60961-0.CrossRef Blau N, van Spronsen FJ, Levy HL: Phenylketonuria. Lancet. 2010, 376: 1417-1427. 10.1016/S0140-6736(10)60961-0.CrossRef
4.
go back to reference Blau N: Phenylketonuria and BH4 deficiencies. 2010, Bremen: Uni-Med Blau N: Phenylketonuria and BH4 deficiencies. 2010, Bremen: Uni-Med
5.
go back to reference Gentile JK, Ten Hoedt AE, Bosch AM: Psychosocial aspects of PKU: hidden disabilities–a review. Mol Genet Metab. 2010, 99 (Suppl 1): S64-S67.CrossRef Gentile JK, Ten Hoedt AE, Bosch AM: Psychosocial aspects of PKU: hidden disabilities–a review. Mol Genet Metab. 2010, 99 (Suppl 1): S64-S67.CrossRef
6.
go back to reference National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. Pediatrics. 2001, 108: 972-982.CrossRef National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16–18, 2000. Pediatrics. 2001, 108: 972-982.CrossRef
7.
go back to reference Blau N, MacDonald A, van Spronsen F: There is no doubt that the early identification of PKU and prompt and continuous intervention prevents mental retardation in most patients. Mol Genet Metab. 2011, 104 (Suppl): S1-CrossRef Blau N, MacDonald A, van Spronsen F: There is no doubt that the early identification of PKU and prompt and continuous intervention prevents mental retardation in most patients. Mol Genet Metab. 2011, 104 (Suppl): S1-CrossRef
8.
go back to reference Giovannini M, Verduci E, Salvatici E, Paci S, Riva E: Phenylketonuria: nutritional advances and challenges. Nutr Metab (Lond). 2012, 9: 7-10.1186/1743-7075-9-7.CrossRef Giovannini M, Verduci E, Salvatici E, Paci S, Riva E: Phenylketonuria: nutritional advances and challenges. Nutr Metab (Lond). 2012, 9: 7-10.1186/1743-7075-9-7.CrossRef
9.
go back to reference Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, Kamp G, Wendel U: Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008, 6: 25-10.1186/1477-7525-6-25.PubMedCentralCrossRef Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, Kamp G, Wendel U: Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008, 6: 25-10.1186/1477-7525-6-25.PubMedCentralCrossRef
10.
go back to reference Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen FJ: Optimizing the use of sapropterin (BH (4)) in the management of phenylketonuria. Mol Genet Metab. 2009, 96: 158-163. 10.1016/j.ymgme.2009.01.002.CrossRef Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen FJ: Optimizing the use of sapropterin (BH (4)) in the management of phenylketonuria. Mol Genet Metab. 2009, 96: 158-163. 10.1016/j.ymgme.2009.01.002.CrossRef
11.
go back to reference GokmenOzel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K: Use of sapropterin in the management of phenylketonuria: seven case reports. Mol Genet Metab. in press GokmenOzel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K: Use of sapropterin in the management of phenylketonuria: seven case reports. Mol Genet Metab. in press
12.
go back to reference van Spronsen FJ, Enns GM: Future treatment strategies in phenylketonuria. Mol Genet Metab. 2010, 99 (Suppl 1): S90-S95.CrossRef van Spronsen FJ, Enns GM: Future treatment strategies in phenylketonuria. Mol Genet Metab. 2010, 99 (Suppl 1): S90-S95.CrossRef
13.
go back to reference Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F: Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010, 99: 109-115. 10.1016/j.ymgme.2009.09.005.CrossRef Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen F: Management of phenylketonuria in Europe: survey results from 19 countries. Mol Genet Metab. 2010, 99: 109-115. 10.1016/j.ymgme.2009.09.005.CrossRef
14.
go back to reference Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M: Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nutr. 2011, 65: 275-278. 10.1038/ejcn.2010.258.CrossRef Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M: Blood phenylalanine control in phenylketonuria: a survey of 10 European centres. Eur J Clin Nutr. 2011, 65: 275-278. 10.1038/ejcn.2010.258.CrossRef
16.
go back to reference van Spronsen FJ, Ahring KK, Gizewska M: PKU–What is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders-ESPKU. J Inherit Metab Dis. 2009, 32: 58-64. 10.1007/s10545-008-0966-y.CrossRef van Spronsen FJ, Ahring KK, Gizewska M: PKU–What is daily practice in various centres in Europe? Data from a questionnaire by the scientific advisory committee of the European Society of Phenylketonuria and Allied Disorders-ESPKU. J Inherit Metab Dis. 2009, 32: 58-64. 10.1007/s10545-008-0966-y.CrossRef
17.
go back to reference Ahring K, Bélanger-Quintana A, Dokoupil K, GokmenOzel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M: Dietary management practices in phenylketonuria across European centres. Clin Nutr. 2009, 28: 231-236. 10.1016/j.clnu.2009.03.004.CrossRef Ahring K, Bélanger-Quintana A, Dokoupil K, GokmenOzel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M: Dietary management practices in phenylketonuria across European centres. Clin Nutr. 2009, 28: 231-236. 10.1016/j.clnu.2009.03.004.CrossRef
18.
go back to reference Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S: Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess. 2004, 8 (iii): 1-121. Pandor A, Eastham J, Beverley C, Chilcott J, Paisley S: Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review. Health Technol Assess. 2004, 8 (iii): 1-121.
20.
go back to reference Di Ciommo V, Forcella E, Cotugno G: Living with phenylketonuria from the point of view of children, adolescents, and young adults: a qualitative study. J Dev Behav Pediatr. 2012, 33: 229-235. 10.1097/DBP.0b013e3182460d8a.CrossRef Di Ciommo V, Forcella E, Cotugno G: Living with phenylketonuria from the point of view of children, adolescents, and young adults: a qualitative study. J Dev Behav Pediatr. 2012, 33: 229-235. 10.1097/DBP.0b013e3182460d8a.CrossRef
21.
go back to reference van Spronsen FJ, Burgard P: The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis. 2008, 31: 673-679. 10.1007/s10545-008-0918-6.CrossRef van Spronsen FJ, Burgard P: The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis. 2008, 31: 673-679. 10.1007/s10545-008-0918-6.CrossRef
22.
go back to reference Sempere A, Arias A, Farré G, García-Villoria J, Rodríguez-Pombo P, Desviat LR, Merinero B, García-Cazorla A, Vilaseca MA, Ribes A, Artuch R, Campistol J: Study of inborn errors of metabolism in urine from patients with unexplained mental retardation. J Inherit Metab Dis. 2010, 33: 1-7.CrossRef Sempere A, Arias A, Farré G, García-Villoria J, Rodríguez-Pombo P, Desviat LR, Merinero B, García-Cazorla A, Vilaseca MA, Ribes A, Artuch R, Campistol J: Study of inborn errors of metabolism in urine from patients with unexplained mental retardation. J Inherit Metab Dis. 2010, 33: 1-7.CrossRef
23.
go back to reference Desviat LR, Pérez B, Gámez A, Sánchez A, García MJ, Martínez-Pardo M, Marchante C, Bóveda D, Baldellou A, Arena J, Sanjurjo P, Fernández A, Cabello ML, Ugarte M: Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. Eur J Hum Genet. 1999, 7: 386-392. 10.1038/sj.ejhg.5200312.CrossRef Desviat LR, Pérez B, Gámez A, Sánchez A, García MJ, Martínez-Pardo M, Marchante C, Bóveda D, Baldellou A, Arena J, Sanjurjo P, Fernández A, Cabello ML, Ugarte M: Genetic and phenotypic aspects of phenylalanine hydroxylase deficiency in Spain: molecular survey by regions. Eur J Hum Genet. 1999, 7: 386-392. 10.1038/sj.ejhg.5200312.CrossRef
24.
go back to reference Wendel U, Langenbeck UL: Towards self-monitoring and self-treatment in phenylketonuria–a way to better diet compliance. Eur J Pediat. 1996, 155 (Suppl 1): S105-S107.CrossRef Wendel U, Langenbeck UL: Towards self-monitoring and self-treatment in phenylketonuria–a way to better diet compliance. Eur J Pediat. 1996, 155 (Suppl 1): S105-S107.CrossRef
25.
go back to reference Ten Hoedt AE, Hollak CE, Boelen CC, Van der Herberg-van de Wetering NA, Ter Horst NM, Jonkers CF, Wijburg FA, Bosch AM: “MY PKU”: increasing self-management in patients with phenylketonuria. A randomized controlled trial. Orphanet J Rare Dis. 2011, 6: 48-10.1186/1750-1172-6-48.PubMedCentralCrossRef Ten Hoedt AE, Hollak CE, Boelen CC, Van der Herberg-van de Wetering NA, Ter Horst NM, Jonkers CF, Wijburg FA, Bosch AM: “MY PKU”: increasing self-management in patients with phenylketonuria. A randomized controlled trial. Orphanet J Rare Dis. 2011, 6: 48-10.1186/1750-1172-6-48.PubMedCentralCrossRef
28.
go back to reference Macdonald A, Davies P, Daly A, Hopkins V, Hall SK, Asplin D, Hendriksz C, Chakrapani A: Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria?. J Hum Nutr Diet. 2008, 21: 351-358. 10.1111/j.1365-277X.2008.00891.x.CrossRef Macdonald A, Davies P, Daly A, Hopkins V, Hall SK, Asplin D, Hendriksz C, Chakrapani A: Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria?. J Hum Nutr Diet. 2008, 21: 351-358. 10.1111/j.1365-277X.2008.00891.x.CrossRef
29.
go back to reference Singh RH, Kable JA, Guerrero NV, Sullivan KM, Elsas LJ: Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls. J Am Diet Assoc. 2000, 100: 797-803. 10.1016/S0002-8223(00)00232-7.CrossRef Singh RH, Kable JA, Guerrero NV, Sullivan KM, Elsas LJ: Impact of a camp experience on phenylalanine levels, knowledge, attitudes, and health beliefs relevant to nutrition management of phenylketonuria in adolescent girls. J Am Diet Assoc. 2000, 100: 797-803. 10.1016/S0002-8223(00)00232-7.CrossRef
30.
go back to reference Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE: Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Human Nutr Dietetics. 2008, 21: 474-485. 10.1111/j.1365-277X.2008.00879.x.CrossRef Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE: Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Human Nutr Dietetics. 2008, 21: 474-485. 10.1111/j.1365-277X.2008.00879.x.CrossRef
31.
go back to reference Crone MR, van Spronsen FJ, Oudshoorn K, Bekhof J, van Rijn G, Verkerk PH: Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis. 2005, 28: 627-637. 10.1007/s10545-005-0014-0.CrossRef Crone MR, van Spronsen FJ, Oudshoorn K, Bekhof J, van Rijn G, Verkerk PH: Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis. 2005, 28: 627-637. 10.1007/s10545-005-0014-0.CrossRef
32.
go back to reference Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, Francis DE, Shortland GJ, Schmidt M, Vail A: How practical are recommendations for dietary control in phenylketonuria?. Lancet. 2002, 360: 55-57. 10.1016/S0140-6736(02)09334-0.CrossRef Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, Francis DE, Shortland GJ, Schmidt M, Vail A: How practical are recommendations for dietary control in phenylketonuria?. Lancet. 2002, 360: 55-57. 10.1016/S0140-6736(02)09334-0.CrossRef
33.
go back to reference Bloom SR, Kuhlthau K, Van Cleave J, Knapp AA, Newacheck P, Perrin JM: Health care transition for youth with special health care needs. J Adolesc Health. 2012, 51: 213-219. 10.1016/j.jadohealth.2012.01.007.CrossRef Bloom SR, Kuhlthau K, Van Cleave J, Knapp AA, Newacheck P, Perrin JM: Health care transition for youth with special health care needs. J Adolesc Health. 2012, 51: 213-219. 10.1016/j.jadohealth.2012.01.007.CrossRef
34.
go back to reference Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, Kamp G, Wendel U: Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008, 26 (6): 25-CrossRef Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, Kamp G, Wendel U: Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008, 26 (6): 25-CrossRef
35.
go back to reference Ievers-Landis CE, Hoff AL, Brez C, Cancilliere MK, McConnell J, Kerr D: Situational analysis of dietary challenges of the treatment regimen for children and adolescents with phenylketonuria and their primary caregivers. J Dev Behav Pediatr. 2005, 26: 186-193. 10.1097/00004703-200506000-00004.CrossRef Ievers-Landis CE, Hoff AL, Brez C, Cancilliere MK, McConnell J, Kerr D: Situational analysis of dietary challenges of the treatment regimen for children and adolescents with phenylketonuria and their primary caregivers. J Dev Behav Pediatr. 2005, 26: 186-193. 10.1097/00004703-200506000-00004.CrossRef
36.
go back to reference Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA: Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008, 23: 1621-1627. 10.1007/s11606-008-0716-8.PubMedCentralCrossRef Okumura MJ, Heisler M, Davis MM, Cabana MD, Demonner S, Kerr EA: Comfort of general internists and general pediatricians in providing care for young adults with chronic illnesses of childhood. J Gen Intern Med. 2008, 23: 1621-1627. 10.1007/s11606-008-0716-8.PubMedCentralCrossRef
37.
go back to reference Hoeks MP, den Heijer M, Janssen MC: Adult issues in phenylketonuria. Neth J Med. 2009, 67: 2-7. Hoeks MP, den Heijer M, Janssen MC: Adult issues in phenylketonuria. Neth J Med. 2009, 67: 2-7.
38.
go back to reference Lee PJ, Ridout D, Walter JH, Cockburn F: Maternal phenylketonuria: report from the United Kingdom Registry 1978–97. Arch Dis Child. 2005, 90: 143-146. 10.1136/adc.2003.037762.PubMedCentralCrossRef Lee PJ, Ridout D, Walter JH, Cockburn F: Maternal phenylketonuria: report from the United Kingdom Registry 1978–97. Arch Dis Child. 2005, 90: 143-146. 10.1136/adc.2003.037762.PubMedCentralCrossRef
39.
go back to reference Gassió R, Campistol J, Vilaseca MA, Lambruschini N, Cambra FJ, Fusté E: Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?. Acta Paediatr. 2003, 92: 1474-1478. 10.1111/j.1651-2227.2003.tb00834.x.CrossRef Gassió R, Campistol J, Vilaseca MA, Lambruschini N, Cambra FJ, Fusté E: Do adult patients with phenylketonuria improve their quality of life after introduction/resumption of a phenylalanine-restricted diet?. Acta Paediatr. 2003, 92: 1474-1478. 10.1111/j.1651-2227.2003.tb00834.x.CrossRef
40.
go back to reference Anjema K, van Rijn M, Verkerk PH, Burgerhof JG, Heiner-Fokkema MR, van Spronsen FJ: PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab. 2011, 104: 231-234. 10.1016/j.ymgme.2011.05.017.CrossRef Anjema K, van Rijn M, Verkerk PH, Burgerhof JG, Heiner-Fokkema MR, van Spronsen FJ: PKU: high plasma phenylalanine concentrations are associated with increased prevalence of mood swings. Mol Genet Metab. 2011, 104: 231-234. 10.1016/j.ymgme.2011.05.017.CrossRef
41.
go back to reference Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ: Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab. 2009, 96: 177-182. 10.1016/j.ymgme.2008.12.019.CrossRef Hoeksma M, Reijngoud DJ, Pruim J, de Valk HW, Paans AM, van Spronsen FJ: Phenylketonuria: High plasma phenylalanine decreases cerebral protein synthesis. Mol Genet Metab. 2009, 96: 177-182. 10.1016/j.ymgme.2008.12.019.CrossRef
42.
go back to reference Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ: Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999, 103: 1169-1178. 10.1172/JCI5017.PubMedCentralCrossRef Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, Bremer HJ: Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999, 103: 1169-1178. 10.1172/JCI5017.PubMedCentralCrossRef
43.
go back to reference Merrick J, Aspler S, Schwarz G: Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria. Int J Adolesc Med Health. 2003, 15: 165-168. Merrick J, Aspler S, Schwarz G: Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria. Int J Adolesc Med Health. 2003, 15: 165-168.
44.
go back to reference Kalkanoğlu HS, Ahring KK, Sertkaya D, Møller LB, Romstad A, Mikkelsen I, Guldberg P, Lou HC, Güttler F: Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr. 2005, 94: 1218-1222.CrossRef Kalkanoğlu HS, Ahring KK, Sertkaya D, Møller LB, Romstad A, Mikkelsen I, Guldberg P, Lou HC, Güttler F: Behavioural effects of phenylalanine-free amino acid tablet supplementation in intellectually disabled adults with untreated phenylketonuria. Acta Paediatr. 2005, 94: 1218-1222.CrossRef
45.
go back to reference Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M, Ahring K: Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers. Mol Genet Metab. 2012, 105: 390-394. 10.1016/j.ymgme.2011.12.004.CrossRef Belanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M, Ahring K: Diet in phenylketonuria: a snapshot of special dietary costs and reimbursement systems in 10 international centers. Mol Genet Metab. 2012, 105: 390-394. 10.1016/j.ymgme.2011.12.004.CrossRef
46.
go back to reference Feillet F, Agostoni C: Nutritional issues in treating phenylketonuria. J Inherit Metab Dis. 2010, 33: 659-664. 10.1007/s10545-010-9043-4.CrossRef Feillet F, Agostoni C: Nutritional issues in treating phenylketonuria. J Inherit Metab Dis. 2010, 33: 659-664. 10.1007/s10545-010-9043-4.CrossRef
47.
go back to reference van Spronsen FJ: Phenylketonuria management from an European perspective: a commentary. Mol Genet Metab. 2010, 100: 107-110. 10.1016/j.ymgme.2010.03.003.CrossRef van Spronsen FJ: Phenylketonuria management from an European perspective: a commentary. Mol Genet Metab. 2010, 100: 107-110. 10.1016/j.ymgme.2010.03.003.CrossRef
Metadata
Title
Requirements for a minimum standard of care for phenylketonuria: the patients’ perspective
Authors
Tobias S Hagedorn
Paul van Berkel
Gregor Hammerschmidt
Markéta Lhotáková
Rosalia Pasqual Saludes
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-191

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue